Investors reacted quickly and negatively when Aptinyx Inc. reported that lead candidate NYX-2925 missed the primary endpoint in a Phase II diabetic peripheral neuropathy (DPN) study Jan. 16, but CEO Norbert Riedel maintained the data for the NMDA receptor modulator in both DPN and fibromyalgia will help build a case for a labeling claim encompassing the spectrum of chronic pain.
The Chicago-area firm saw its stock lose nearly two-thirds of its value, closing down 66.5% on Jan. 16 at $5.98...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
